Evidence map›Paper›PMID 39012045›Full record

ArticleInfluenza and other respiratory viruses2024

Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022.

Ryan Sandford, Ruchi Yadav, Emma K Noble, Kelsey Sumner, Devyani Joshi, Sara Y Tartof, Karen J Wernli, Emily T Martin, Manjusha Gaglani, Richard K Zimmerman and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Ryan SandfordCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-1904-9501
Ruchi YadavCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Emma K NobleCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Kelsey SumnerCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-4479-897X
Devyani JoshiCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Sara Y TartofDepartment of Research & Evaluation, Kaiser Permanente Southern California, Yorba Linda, California, USA.
Karen J WernliKaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Emily T MartinUniversity of Michigan School of Public Health, Ann Arbor, Michigan, USA.ORCID 0000-0002-5771-8895
Manjusha GaglaniBaylor Scott & White Health, Temple, Texas, USA.
Richard K ZimmermanUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
H Keipp TalbotVanderbilt University Medical Center, Nashville, Tennessee, USA.
Carlos G GrijalvaVanderbilt University Medical Center, Nashville, Tennessee, USA.
Edward A BelongiaMarshfield Clinic Research Institute, Marshfield, Wisconsin, USA.ORCID 0000-0001-7478-0415
Christina CarlsonCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Melissa CoughlinCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Brendan FlanneryCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Brad PearceRollins School of Public Health, Atlanta, Georgia, USA.
Eric RogierCenters for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
CDC HHS 75D30121C11513CDC HHS 75D30121C11519CDC HHS 75D30121C11529CDC HHS 75D30121C11909CDC HHS 75D30121C12246CDC HHS 75D30121C12279CDC HHS 75D30121C12339National Center for Advancing Translational Sciences Clinical Translational Science 5UL1TR002243-03NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR002243NIH HHS UL1TR001857
6 · The paper itself

Abstract

We describe humoral immune responses in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS-CoV-2 infection.

Indexed as

Antibodies, ViralCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusAdultAgedAntibody FormationCoronavirus Nucleocapsid ProteinsFemaleHumansImmunity, HumoralMaleMiddle AgedYoung AdultAntibodies, ViralCoronavirus Nucleocapsid ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID‐19immune responseOmicron subvariantsSARS‐CoV‐2 infection

Identifiers

PMID39012045
PMCPMC11250392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.